• In recent days, Moderna announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which will provide up to US$50 million to support preclinical and Phase 1 development of its investigational Bundibugyo ebolavirus (BDBV) vaccine candidate.
• This partnership highlights how Moderna is using its mRNA platform beyond respiratory viruses, extending into emerging infectious diseases such as Ebola during an active outbreak in the Democratic Republic of Congo.
• We’ll now examine how CEPI’s US$50 million commitment to Moderna’s Bundibugyo ebolavirus vaccine program could influence the company’s broader investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Moderna Investment Narrative Recap

To own Moderna, you have to believe its mRNA platform can broaden beyond seasonal COVID-19 and RSV shots into a more diversified, less volatile revenue mix. The CEPI partnership around a Bundibugyo ebolavirus vaccine showcases that ambition, but the US$50 million commitment is small relative to Moderna’s losses and does not change that the key near term catalyst remains regulatory and commercial progress in its core respiratory vaccine portfolio, while the biggest risk is continued revenue and earnings pressure if new launches underperform.

The CEPI collaboration sits alongside a tougher recent backdrop, including Q1 2026 revenue of US$389 million and a net loss of US$1,343 million, as well as an FDA Refusal-to-File for the mRNA-1010 flu vaccine. That influenza setback is especially relevant here, because it highlights how regulatory friction in Moderna’s main respiratory programs can weigh more heavily on the near term story than early stage, externally funded efforts in emerging infectious diseases like Ebola.

Yet despite these encouraging pipeline signals, investors should also be aware that...

Moderna's narrative projects $3.2 billion revenue and $407.1 million earnings by 2029.

Uncover how Moderna's forecasts yield a $46.10 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$7.9 billion by 2029, so this CEPI-backed Ebola work may either support that ambition or prompt a rethink, especially when you contrast it with concerns about high R&D costs and regulatory uncertainty.

Explore 6 other fair value estimates on Moderna - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.